基本信息
浏览量:4
职业迁徙
个人简介
Research Summary:
I have made many contributions to understanding of prion diseases for over 20 years, significantly including the discovery that the normal cellular isoform of the prion protein participates in cell activation (Cashman et al, Cell 1990) and lymphoid differentiation (Dodelet and Cashman, Blood 1998). These and other papers have been considered foundational in the new science of prion neuroimmunology, and have also been cited by scientists and policy makers as evidence for the prion infectablity of peripheral lymphoid and bone marrow cells. More recently, I have identified an immunological epitope unique to the disease-associated isoform of the prion protein, with potential for use in non-invasive diagnosis and treatment of the prion disorders (Paramithiotis et al, Nature Medicine 2003; Cashman and Caughey, Nature Reviews in Drug Discovery 2004; Griffin and Cashman Expert Opinion on Biological Therapeutics 2006). Other recent prion work includes the identification of a cell surface receptor for these proteins (patent pending), copolymer-based therapies for prion disease (patent awarded), a prion peptide experimental system for studying amyloid formation (Zou et al, Europ Biochem 2001), an enhanced in vitro prion protein conversion system (Zou and Cashman, J Biol Chem 2002; patent pending), and the development of a novel method for detecting aggregated misfolded proteins, including prions, named Epitope Protection (patent pending). As a clinical neurologist concerned with the public health impact of newly emerging prion diseases, I have published numerous well-cited medical articles on this subject (e.g., Cashman CMAJ 1997; Coulthart and Cashman CMAJ 2001). I co-founded in 1998 the Canadian CJD Surveillance System, and I have I have made many contributions to understanding of prion diseases for over 20 years, significantly including the discovery that the normal cellular isoform of the prion protein participates in cell activation (Cashman et al, Cell 1990) and lymphoid differentiation (Dodelet and Cashman, Blood 1998). These and other papers have been considered foundational in the new science of prion neuroimmunology, and have also been cited by scientists and policy makers as evidence for the prion infectablity of peripheral lymphoid and bone marrow cells. More recently, I have identified an immunological epitope unique to the disease-associated isoform of the prion protein, with potential for use in non-invasive diagnosis and treatment of the prion disorders (Paramithiotis et al, Nature Medicine 2003; Cashman and Caughey, Nature Reviews in Drug Discovery 2004; Griffin and Cashman Expert Opinion on Biological Therapeutics 2006). Other recent prion work includes the identification of a cell surface receptor for these proteins (patent pending), copolymer-based therapies for prion disease (patent awarded), a prion peptide experimental system for studying amyloid formation (Zou et al, Europ Biochem 2001), an enhanced in vitro prion protein conversion system (Zou and Cashman, J Biol Chem 2002; patent pending), and the development of a novel method for detecting aggregated misfolded proteins, including prions, named Epitope Protection (patent pending). As a clinical neurologist concerned with the public health impact of newly emerging prion diseases, I have published numerous well-cited medical articles on this subject (e.g., Cashman CMAJ 1997; Coulthart and Cashman CMAJ 2001). I co-founded in 1998 the Canadian CJD Surveillance System, and I have served as an expert for the Canadian government and international industry on these diseases (e.g., the “”Cashman Report”” on risks of transmission of prion disease through blood and blood products for Health Canada 1999, McDonald’s Corporation Scientific Advisory Committee since 2001). I am the Scientific Director of PrioNet Canada, a Network of Centres of Excellence awarded in November 2005. Caprion Pharmaceuticals in Montreal was initially founded in 1998 to commercialize my prion discoveries. Amorfix Life Sciences was founded in 2004 to commercialize my work in detection and treatment of protein misfolding diseases, including prion disorders and other neurodegenerative diseases. I am Chief Scientific Officer of Amorfix, which became public on the TSX-V exchange in October 2005, and now has a market capitalization of ~CAD 50 M. Both Caprion and Amorfix technology emerged from programs originally funded by CIHR.
I have made many contributions to understanding of prion diseases for over 20 years, significantly including the discovery that the normal cellular isoform of the prion protein participates in cell activation (Cashman et al, Cell 1990) and lymphoid differentiation (Dodelet and Cashman, Blood 1998). These and other papers have been considered foundational in the new science of prion neuroimmunology, and have also been cited by scientists and policy makers as evidence for the prion infectablity of peripheral lymphoid and bone marrow cells. More recently, I have identified an immunological epitope unique to the disease-associated isoform of the prion protein, with potential for use in non-invasive diagnosis and treatment of the prion disorders (Paramithiotis et al, Nature Medicine 2003; Cashman and Caughey, Nature Reviews in Drug Discovery 2004; Griffin and Cashman Expert Opinion on Biological Therapeutics 2006). Other recent prion work includes the identification of a cell surface receptor for these proteins (patent pending), copolymer-based therapies for prion disease (patent awarded), a prion peptide experimental system for studying amyloid formation (Zou et al, Europ Biochem 2001), an enhanced in vitro prion protein conversion system (Zou and Cashman, J Biol Chem 2002; patent pending), and the development of a novel method for detecting aggregated misfolded proteins, including prions, named Epitope Protection (patent pending). As a clinical neurologist concerned with the public health impact of newly emerging prion diseases, I have published numerous well-cited medical articles on this subject (e.g., Cashman CMAJ 1997; Coulthart and Cashman CMAJ 2001). I co-founded in 1998 the Canadian CJD Surveillance System, and I have I have made many contributions to understanding of prion diseases for over 20 years, significantly including the discovery that the normal cellular isoform of the prion protein participates in cell activation (Cashman et al, Cell 1990) and lymphoid differentiation (Dodelet and Cashman, Blood 1998). These and other papers have been considered foundational in the new science of prion neuroimmunology, and have also been cited by scientists and policy makers as evidence for the prion infectablity of peripheral lymphoid and bone marrow cells. More recently, I have identified an immunological epitope unique to the disease-associated isoform of the prion protein, with potential for use in non-invasive diagnosis and treatment of the prion disorders (Paramithiotis et al, Nature Medicine 2003; Cashman and Caughey, Nature Reviews in Drug Discovery 2004; Griffin and Cashman Expert Opinion on Biological Therapeutics 2006). Other recent prion work includes the identification of a cell surface receptor for these proteins (patent pending), copolymer-based therapies for prion disease (patent awarded), a prion peptide experimental system for studying amyloid formation (Zou et al, Europ Biochem 2001), an enhanced in vitro prion protein conversion system (Zou and Cashman, J Biol Chem 2002; patent pending), and the development of a novel method for detecting aggregated misfolded proteins, including prions, named Epitope Protection (patent pending). As a clinical neurologist concerned with the public health impact of newly emerging prion diseases, I have published numerous well-cited medical articles on this subject (e.g., Cashman CMAJ 1997; Coulthart and Cashman CMAJ 2001). I co-founded in 1998 the Canadian CJD Surveillance System, and I have served as an expert for the Canadian government and international industry on these diseases (e.g., the “”Cashman Report”” on risks of transmission of prion disease through blood and blood products for Health Canada 1999, McDonald’s Corporation Scientific Advisory Committee since 2001). I am the Scientific Director of PrioNet Canada, a Network of Centres of Excellence awarded in November 2005. Caprion Pharmaceuticals in Montreal was initially founded in 1998 to commercialize my prion discoveries. Amorfix Life Sciences was founded in 2004 to commercialize my work in detection and treatment of protein misfolding diseases, including prion disorders and other neurodegenerative diseases. I am Chief Scientific Officer of Amorfix, which became public on the TSX-V exchange in October 2005, and now has a market capitalization of ~CAD 50 M. Both Caprion and Amorfix technology emerged from programs originally funded by CIHR.
研究兴趣
论文共 46 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ACS chemical neuroscienceno. 15 (2023): 2603-2617
Beibei Zhao,Catherine M. Cowan, Juliane A. Coutts,Darren D. Christy, Ananya Saraph,Shawn C. C. Hsueh, Stephen S. Plotkin,Ian R. Mackenzie,Johanne M. Kaplan,Neil R. Cashman
Acta Neuropathologica Communicationsno. 1 (2023): 1-17
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiquespp.1-28, (2023)
Handbook of clinical neurology (2023): 89-99
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn